Compare STAA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | DSGN |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 819.6M |
| IPO Year | 1995 | 2021 |
| Metric | STAA | DSGN |
|---|---|---|
| Price | $28.20 | $15.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $22.81 | $15.25 |
| AVG Volume (30 Days) | ★ 788.1K | 522.6K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $3.11 |
| 52 Week High | $30.81 | $17.25 |
| Indicator | STAA | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 67.91 |
| Support Level | $23.75 | $9.25 |
| Resistance Level | $30.81 | $17.25 |
| Average True Range (ATR) | 1.13 | 1.24 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 92.21 | 75.94 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.